News | May 21, 2008

First Patients Enrolled in MIV Therapeutics VESTASYNC II Study

May 22, 2008 - MIV Therapeutics Inc. has enrolled the first patients in the registration trial of its VESTAsync polymer-free drug-eluting stent, as the company accelerates its timeline for the VESTASYNC II trial after positive nine-month human safety and efficacy data were reported in March at the American College of Cardiology meeting.

The VESTASYNC II trial is designed to test the efficacy of the VESTAsync in a sufficient number of patients to form the basis of a regulatory filing for marketing approval in Europe. It is anticipated that these patient data will also be part of an eventual submission to the U.S. FDA.

Alexandre Abizaid, M.D., Ph.D., chief of coronary intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, is a principal investigator in this 120-patient, multi-center, randomized, controlled study. In this study 90 patients will receive the VESTAsync nano-porous hydroxyapatite (HAp) coated drug-eluting stent, while 30 patients will receive the company’s VESTAcor stent, the company’s nano-porous HAp coated stent, which contains no drug. The primary endpoint is late lumen loss as measured by quantitative coronary angiography (QCA) at nine months. Secondary endpoints will include major adverse cardiac events and volumetric obstruction. Intravascular ultrasound (IVUS), optical coherent tomography (OCT) and physiological substudies are also expected to be performed.

“We are accelerating this registration trial due to the results obtained with the VESTAsync in our pilot study after nine-month patient follow up, and the potential to address safety issues in currently marketed drug-eluting stents using polymers to deliver drug,” commented Dr. Mark Landy, president and chief executive officer of MIV Therapeutics. “Our stent is a polymer-free, nanoscale, microporous hydroxyapatite stent that has the ability to deliver a much smaller effective dose of drug, in fact 60 percent less, with the safety of bare-metal stents, and probably requires only short-term anticoagulant therapy. Currently available drug-eluting stents require patients to take anticoagulants, such as Plavix, for as long as one year. We intend for the data obtained from this study to support an application for CE mark of the VESTAsync by the end of 2009 and are looking forward eventually to offering patients and physicians a superior alternative to currently available products,” Dr. Landy added.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init